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Introduction: Although the incidence of peripheral squamous 
cell carcinomas (p-SqCCs) of the lung has increased over recent 
years, clinicopathological factors influencing prognosis of resected 
p-SqCCs remain unclear.
Methods: We examined 280 patients who underwent complete 
resection of SqCCs and analyzed the clinicopathological features in 
relation to their overall survival (OS) and recurrence-free survival 
(RFS) according to the primary location.
Results: Multivariate analysis of all stages of p-SqCCs patients 
revealed that high serum squamous cell carcinoma antigen (SCC) 
level (OS; p < 0.01, RFS; p < 0.01), vascular invasion (OS; p < 0.01, 
RFS; p < 0.01), pleural invasion (OS; p = 0.03, RFS; p = 0.01), nodal 
metastasis (OS; p = 0.02) and complication with lung disease (OS; 
p < 0.01) were independently unfavorable prognostic factors. Among 
stage I p-SqCCs patients, high serum SCC level (OS; p < 0.01, RFS; 
p < 0.01), vascular invasion (RFS; p < 0.01) and pleural invasion 
(RFS; p = 0.01) were also strongly correlated with poor prognosis 
independently. When we reevaluated the survival rate, T1 p-SqCCs 
with high serum SCC level or vascular invasion can be upgraded to 
T2a. Patients with stage IB had a significantly poorer prognosis than 
stage IA (5-year RFS; 61.4 % versus 76.6 %, p < 0.05).
Conclusion: High serum SCC level, pleural and vascular invasions 
were independent poor prognostic factors for completely resected 
p-SqCCs. T1 p-SqCCs with high serum SCC level or vascular inva-
sion should be upgraded to T2a, which accurately reflect survival sta-
tus among patients with p-SqCCs.
Key Words: Peripheral squamous cell carcinoma, Pleural invasion, 
Vascular invasion.
(J Thorac Oncol. 2014;9: 1779–1787)
Lung cancer is the most common cause of cancer-related death worldwide and squamous cell carcinomas (SqCCs) 
of the lung account for 20–30% of non–small-cell lung can-
cers (NSCLC).1,2 SqCCs can be classified into the central 
type (c-SqCCs) and the peripheral type (p-SqCCs) accord-
ing to the primary location. Although the majority of SqCCs 
of the lung have histologically been reported to be c-SqCCs, 
the incidence of p-SqCCs has increased over recent years.3,4 
Several reports have revealed a low prevalence of lymph node 
metastasis in p-SqCCs, especially in tumors 2 cm or less in 
diameter.3,5,6 These facts support the idea that p-SqCCs remain 
localized and grow slowly compared with lung adenocarci-
noma.7,8 However, the characteristics and biological behav-
iors of p-SqCCs including prognostic factors remain to be 
elucidated.
Pathologically proven lymphovascular and pleural inva-
sion are generally correlated with poor outcome and they 
could predict cancer recurrence in NSCLC. Visceral pleural 
invasion is defined as invasion beyond the elastic layer and 
T1 tumors with pleural invasion is upgraded to T2a in the 7th 
TNM classification. Vascular invasion is also significantly 
correlated with cancer recurrence in early stage NSCLC.9,10 
Although vascular and pleural invasion are useful prognostic 
factors for NSCLC, this has not yet been established among 
p-SqCCs patients. In this retrospective study, we evaluated 
several clinicopathological variables in patients with p-SqCCs 
in an attempt to identify reliable prognostic factors.
PATIENTS AND METHODS
A total of 280 patients were enrolled in this retrospec-
tive study. They all underwent complete resection of SqCCs 
from January 1995 to December 2011 at our two institutes. 
All the patients had a solitary lesion, and patients who had 
received preoperative chemotherapy or thoracic radiother-
apy were excluded. Almost all the patients whose tumor was 
pathologically diagnosed as over stage II SqCC received 
platinum-based doublet adjuvant chemotherapy after surgi-
cal resection. A p-SqCC was defined as a tumor located in or 
more peripheral to the fourth branching bronchus according 
to the previous reports.4,11,12 We retrospectively determined the 
location based on the findings of preoperative bronchoscopy 
and radiography. Some cases which were difficult to detect 
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the location definitely due to its size were excluded. In our 
institutes, the serum levels of some tumor markers were rou-
tinely measured within 1-month period before surgery. The 
cutoff value of carcinoembryonic antigen (CEA) was 5.5 ng/
ml and that of squamous cell carcinoma antigen (SCC) was 
1.5 ng/ml. The preoperative evaluation included physical 
examination, blood chemistry analysis, bronchofiberscopy, 
chest radiography, computed tomography (CT) examinations 
of the chest, magnetic resonance imaging of the brain and 
bone scintigraphy. Patients who underwent partial resection 
were excluded because the systematic lymph nodes dissection 
was insufficiently performed in many cases. We surveyed the 
patients at 3-month interval for the first 2 years and at 6-month 
interval thereafter. The follow-up evaluation included physical 
examination, chest CT, and blood examination. Whenever any 
symptoms or signs of recurrence were detected, further evalu-
ations were performed. We diagnosed the tumor recurrence 
on the basis of diagnostic imaging findings, and confirmed the 
diagnosis pathologically when clinically feasible.
Data collections and analyses were approved and, as the 
research was a retrospective chart and specimen review and no 
personally identifiable information was included, the need to 
obtain informed consent from each patient was waived by the 
institutional review board in March 2014.
We reviewed all the available pathology slides of resected 
specimens in this study. After fixing the specimens with 10% 
formalin and embedding them in paraffin, serial 4-μm sections 
were stained with hematoxylin and eosin, and elastica van 
Gieson to assess the degree of pleural and vascular invasion 
(Fig. 1). In our two institutes, two pathologists who specialize 
in lung pathology diagnosed vascular invasion mainly based 
on the histological structure and reach a consensus without 
immunohistochemical staining. Adhesion of tumor to endo-
thelial cells is an important finding when they diagnose it as 
a presence of vascular invasion. Pathological slides stained by 
elastica van Gieson also help them diagnose it. When needed, 
we additionally stained them with D2-40 to evaluate the extent 
of lymphatic permeation. Pathological diagnoses were based 
on the criteria of the World Health Organization guidelines. 
Disease stages were classified according to the current 7th 
Edition of the Union for International Cancer Control TNM 
classification system.
Overall survival (OS) was measured from the day of 
pulmonary resection to the date of death from any cause or 
the date on which the patient was last known to be alive. 
The recurrence-free survival (RFS) was measured as the 
interval between the date of resection and the date of recur-
rence diagnosis, or the date of death from any cause, or the 
last date on which the patient was last known to be alive 
and disease-free confirmed on the last CT before death. 
All tests were two-sided, and p values of less than 0.05 
were considered to be statistically significant. Univariate 
survival analysis was based on a Cox proportional hazard 
regression model. The multivariate Cox forward stepwise 
regression model was used to detect independent predic-
tors of survival. Survival curves were plotted according to 
the Kaplan–Meier method and compared using the log-rank 
test. Data were analyzed with statistical Standard Package 
Source Solution Software (SPSS for standard version 21.0; 
SPSS Inc., Chicago, IL).
RESULTS
Patient Characteristics
The study cohort included 245 men and 35 women, 
with a median age of 69 years (range, 37–91 years). The 
follow-up period for the patients in this study ranged from 3 
to 192 months. The median follow-up time was 64 months. 
Almost all the patients had a smoking history (264 patients; 
94 %). The median value of Brinkman Index among the 
patients was 1000 (range, 0–9200). In our survey, a patient 
with pulmonary disease was defined as having chronic 
obstructive pulmonary disease or idiopathic pulmonary 
fibrosis. The clinicopathological features among the enrolled 
patients are listed in Table 1.
FIGURE 1.  Representative elastica van Gieson staining. Pleural invasion (A) and vascular invasion (B) case of peripheral squa-
mous cell carcinoma of the lung.
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Comparison of Clinicopathological 
Factors Between p-SqCCs and c-SqCCs
On univariate analysis of clinicopathological factors 
of all stages with p-SqCCs for OS and RFS, older age (haz-
ard ratio [HR], 1.76; p = 0.03 for OS; HR, 1.72; p = 0.02 
for RFS), complication with pulmonary disease (HR, 2.35; 
p < 0.01 for OS; HR, 1.88; p < 0.01 for RFS), high serum CEA 
level (HR, 1.94; p = 0.01 for OS), high serum SCC level (HR, 
2.35; p < 0.01 for OS; HR, 2.19; p < 0.01 for RFS), nodal metas-
tasis (HR, 3.06; p = 0.01 for OS; HR, 1.78; p = 0.03 for RFS), 
pathological stage (HR, 1.67; p = 0.03 for RFS), vascular inva-
sion (HR, 2.08; p < 0.01 for OS; HR, 2.45; p < 0.01 for RFS), 
and pleural invasion (HR, 1.80; p = 0.02 for OS; HR, 2.09; 
p < 0.01 for RFS) were significantly associated with poorer 
outcome (Table 2). Of 202 tumors, 130 tumors were diag-
nosed as pathological stage I. Among the patients with stage 
I p-SqCCs, older age (HR, 2.16; p = 0.03 for OS; HR, 2.49; 
p < 0.01 for RFS), high serum SCC level (HR, 3.14; p < 0.01 
for OS; HR, 2.53; p < 0.01 for RFS), vascular invasion (HR, 
2.22; p = 0.04 for RFS), and pleural invasion (HR, 2.06; 
p = 0.03 for RFS) were significantly associated with poorer 
prognosis (Table 2).
On the other hand, univariate analysis of clinicopatho-
logical factors of all stages with c-SqCCs demonstrated older 
age (HR, 2.00; p < 0.05 for OS; HR, 2.31; p = 0.02 for RFS), 
high CEA level (HR, 2.28; p = 0.02 for OS), nodal metastasis 
(HR, 2.49; p < 0.01 for OS; HR, 2.72; p < 0.01 for RFS), path-
ological stage (HR, 2.05; p = 0.04 for OS; HR, 2.11; p = 0.03 
for RFS), and vascular invasion (HR, 2.24; p = 0.02 for OS; 
HR, 2.46; p < 0.01 for RFS) were significantly associated with 
poorer outcome (Table 2). Thirty eight tumors were diagnosed 
as pathological stage I. Male (HR, 16.5; p = 0.02 for OS; HR, 
34.5; p = 0.01 for RFS) and vascular invasion (HR, 10.7; p < 
0.01 for OS; HR, 8.12; p < 0.01 for RFS) were strongly corre-
lated with unfavorable prognosis. Preoperative SCC level and 
the degree of pleural invasion were not statistically associated 
with survival status (Table 2).
The survival curves for 280 patients with SqCCs accord-
ing to the primary site were shown in Supplemental Fig. 1A–D. 
Supplemental Fig. 1A, B shows the OS and RFS curves among 
all patients. Five-year OS rates of p-SqCCs and c-SqCCs 
patients were 69.2 % and 61.0 %, 5-year RFS rate were 60.9 
% and 58.5 % respectively. There was no statistical differ-
ence for OS (p = 0.07) and RFS (p = 0.36). Survival curves 
among stage I patients were plotted as shown in Supplemental 
Fig. 1C, D. The differences of survival status between stage I 
p-SqCCs and c-SqCCs were not detected statistically for OS 
(p = 0.78) and RFS (p = 0.88).
Identification of Independent Prognostic 
Factors Among p-SqCC Patients
We performed multivariate analysis of these factors 
among p-SqCCs patients with all stages and detected indepen-
dent prognostic factors using Cox forward stepwise regression 
model. Complication with pulmonary disease (HR, 2.98; p < 0.01 
for OS), the high serum SCC level (HR, 2.16; p < 0.01 
for OS; HR, 1.89; p < 0.01 for RFS), nodal metastasis (HR, 
1.97; p = 0.02 for OS), vascular invasion (HR, 2.19; p < 0.01 
for OS; HR, 2.18; p < 0.01 for RFS), and pleural invasion 
(HR, 1.83; p = 0.03 for OS; HR, 1.77; p = 0.01 for RFS) 
were confirmed as independent prognostic factors (Table 3). 
Among the patients with pathologically stage I p-SqCCs, the 
high SCC level (HR, 2.53; p < 0.01 for OS; HR, 1.95; p < 0.01 
for RFS), vascular invasion (HR, 2.11; p < 0.01 for RFS), and 
pleural invasion (HR, 1.78; p = 0.01 for RFS) were detected to 
be independent prognostic factors (Table 3). Generally iden-
tified prognostic factors such as larger tumor diameter and 
lymphatic permeation were not significantly correlated with 
poor prognosis in OS and RFS. The representative RFS curves 
using the Kaplan–Meier method and compared using the log-
rank test are shown in Fig. 2A–F, and OS curves are also dem-
onstrated in Supplemental Fig. 2A–F.
New Staging Classification for Stage I 
p-SqCCs Based on Prognostic Factors
We examined our data again using our revised staging 
criteria for T1 p-SqCCs with high serum SCC or vascular 
invasion, upgrading them to T2a, as was done for cases with 
pleural invasion. Not only tumors measuring greater than3 cm 
are associated with pleural invasion, but also those with high 
preoperative serum SCC levels or vascular invasion should be 
upgraded. With regards to tumor recurrence after lung resec-
tion, patients with new T2a had a comparatively poorer prog-
nosis than those with new T1 (5-year RFS; 61.4 % versus 76.5 
%, p = 0.09) (Fig. 3A, B), and patients with new stage IB (new 
T2aN0) had a significantly poorer prognosis than those with 
new stage IA (new T1N0) (5-year RFS: 61.4 % versus 76.6 
%, p < 0.05) (Fig. 3C, D). However, according to our pro-
posal, T-status (p = 0.20) and pathological stage (p = 0.22) did 
not accurately reflect OS status among patients with stage I 
p-SqCCs (data not shown).
DISCUSSION
The incidence of p-SqCCs has increased over recent 
years. Some reports have showed there are significant differ-
ences in clinicopathological and biological features between 
central and peripheral SqCCs.4,13 We retrospectively evalu-
ated several clinicopathological variables particularly among 
p-SqCCs patients to seek reliable prognostic factors. From 
TABLE 1.   Characteristics of 280 Patients with Completely 
Resected Squamous Cell Carcinoma of the Lung
Variables Numbers (n = 280)
Sex male/female 245/35
Median age (range) 69 (37–91)
Brinkman index (range) 1000 (0–9200)
Primary lesion peripheral/central 202/78
Surgery type lobectomy/pneumonectomy/
segmentectomy
224/21/35
Pulmonary disease present/absent 77/203
Tumor diameter (cm) ≤2/2<, ≤3/3<, ≤5/5<, ≤7/7< 57/67/117/27/12
Nodal metastasis N0/N1/N2 219/28/33
Pathological stage IA/IB/IIA/IIB/IIIA/IIIB 95/73/28/37/41/6
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TABLE 2.  Overall Survival Rate and Recurrence-Free Survival Rate in Peripheral Squamous Cell Carcinoma Patients of All Stages 
and Pathological Stage I in Clinicopathological Factors According to the Primary Lesion
Variables
p-SqCCs c-SqCCs
n
OS RFS
n
OS RFS
HR (95%CI) p -value HR (95%CI) p -value HR (95%CI) p -value HR (95%CI) p value
All stages
Sex
Male 171 1.36 (0.62–3.00) 0.44 1.29 (0.64–2.58) 0.48 74 1.41 (0.42–4.68) 0.58 1.46 (0.44–4.84) 0.54
Female 31 1 1 4 1 1
Age (y)
≥70 100 1.76 (1.05–2.93) 0.03 1.72 (1.09–2.73) 0.02 33 2.00 (1.01–3.95) <0.05 2.31 (1.17–4.55) 0.02
<70 102 1 1 45 1 1
Smoking status (BI)
≥1000 106 1.12 (0.68–1.85) 0.66 1.20 (0.77–1.88) 0.41 51 1.45 (0.70–2.99) 0.31 1.43 (0.70–3.18) 0.32
<1000 96 1 1 27 1 1
Surgery type
Limited 28 1.35 (0.54–3.38) 0.52 1.02 (0.49–2.13) 0.96 7 2.10 (0.62–7.12) 0.24 1.66 (0.49–5.62) 0.41
Standard 174 1 1 71 1 1
Pulmonary disease
Present 62 2.35 (1.42–3.91) <0.01 1.88 (1.19–2.97) <0.01 15 1.28 (0.58–2.82) 0.54 1.04 (0.46–2.39) 0.92
Absent 140 1 1 63 1 1
Serum CEA (ng/ml)
>5.5 52 1.94 (1.14–3.30) 0.01 1.45 (0.88–2.38) 0.14 22 2.28 (1.16–4.48) 0.02 1.91 (0.97–3.76) 0.06
≤5.5 150 1 1 56 1 1
Serum SCC (ng/ml)
>1.5 77 2.35 (1.42–3.89) <0.01 2.19 (1.40–3.43) <0.01 48 1.49 (0.76–2.91) 0.25 1.80 (0.93–3.47) 0.08
≤1.5 125 1 1 30 1 1
Tumor diameter (cm)
>3 109 1.35 (0.81–2.24) 0.25 1.33 (0.85–2.10) 0.21 48 1.37 (0.68–2.76) 0.38 1.63 (0.80–3.33) 0.18
≤3 93 1 1 30 1 1
Nodal metastasis
Present 34 3.06 (1.18–3.79) 0.01 1.78 (1.04–3.05) 0.03 27 2.49 (1.27–4.87) <0.01 2.72 (1.40–5.30) <0.01
Absent 168 1 1 51 1 1
Pathological stage
II–III 72 1.48 (0.89–2.45) 0.13 1.67 (1.07–2.62) 0.03 40 2.05 (1.03–4.09) 0.04 2.11 (1.06–4.19) 0.03
I 130 1 1 38 1 1
Lymphatic permeation
Present 60 1.15 (0.68–1.97) 0.59 1.18 (0.74–1.90) 0.48 26 1.96 (1.00–3.87) 0.05 2.03 (1.04–3.95) 0.04
Absent 142 1 1 52 1 1
Vascular invasion
Present 46 2.08 (1.19–3.62) <0.01 2.45 (1.50–3.98) <0.01 23 2.24 (1.15–4.39) 0.02 2.46 (1.27–4.76) <0.01
Absent 156 1 1 55 1 1
Pleural invasion
Present 60 1.80 (1.08–3.02) 0.02 2.09 (1.32–3.28) <0.01 30 1.41 (0.72–2.76) 0.32 1.45 (0.75–2.82) 0.27
Absent 142 1 1 48 1 1
Pathological stage I
Sex
Male 110 1.42 (0.43–4.67) 0.56 1.71 (0.53–5.56) 0.36 37 16.5 (1.50–182) 0.02 34.5 (2.15–551) 0.01
Female 20 1 1 1 1 1
Age (y)
≥70 64 2.16 (1.09–4.27) 0.03 2.49 (1.31–4.76) <0.01 17 1.97 (0.66–5.89) 0.23 1.90 (0.63–5.68) 0.25
<70 66 1 1 21 1 1
(Continued)
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our results, some considerable differences in prognostic fac-
tors were observed between p-SqCCs and c-SqCCs (Table 2). 
Preoperative high serum SCC level, vascular invasion, and 
pleural invasion were strongly correlated with unfavorable 
outcome for p-SqCCs. High SCC level and pleural inva-
sion were not identified as poor prognostic factors among 
patients with c-SqCCs. In the current TMN classification, 
T1 tumors with visceral pleural invasion are classified as 
T2a. Pleural indentation on chest CT scans is a characteristic 
finding of lung adenocarcinoma, which is strongly associ-
ated with pleural invasion pathologically.14 This feature is 
rarely observed among chest CT of p-SqCCs. It is generally 
true that SqCCs make relatively slower progress and have a 
lower frequency of invasion than other subtypes.7 However, 
Kawase et al.15 reported that more than one-third of lung 
cancers with chest wall invasion are SqCCs (37%).This fre-
quency indicates that peripheral SqCCs are more likely to 
invade surrounding tissues beyond the elastic layer than lung 
adenocarcinomas. Our survey revealed that p-SqCCs with 
pleural invasion are more likely to recur than those without 
it. Pleural invasion would be considered to be an essential 
step in progression and metastasis of p-SqCCs. Furthermore 
some reports demonstrated that pathologically proven vascu-
lar invasion is significantly correlated with cancer recurrence 
in stage I NSCLC.9,10 We showed vascular invasion also plays 
an important key role in the tumor invasion and metastasis of 
p-SqCCs. Funai et al.4 showed that the survival proportions 
did not differ significantly between central and peripheral 
SqCCs without nodal metastases; however, the 5-year sur-
vival state in the case of N1 classification was significantly 
better in the central type (71 %) than in the peripheral type 
(32 %). Saijo et al.13 reported that different expression pat-
terns of cytokeratin 7 and 19 between these SqCC types by 
tissue microarray analysis. From these two reports and our 
Smoking status (BI)
≥1000 65 1.14 (0.44–2.94) 0.68 1.49 (0.59–3.80) 0.73 24 1.82 (0.53–6.25) 0.55 1.70 (0.50–5.75) 0.40
<1000 65 1 1 14 1 1
Surgery type
Limited 26 1.16 (0.41–3.32) 0.78 1.50 (0.35–1.97) 0.67 5 1.36 (0.55–2.32) 0.68 1.50 (0.45–1.96) 0.64
Standard 104 1 1 33 1 1
Pulmonary disease
Present 41 1.89 (0.97–3.68) 0.06 1.48 (0.80–2.75) 0.21 6 1.27 (0.28–5.76) 0.76 1.35 (0.30–6.15) 0.70
Absent 89 1 1 32 1 1
Serum CEA (ng/ml)
>5.5 31 1.81 (0.88–3.73) 0.10 1.34 (0.67–2.67) 0.40 7 1.95 (0.60–6.35) 0.27 1.94 (0.60–6.31) 0.27
≤5.5 99 1 1 31 1 1
Serum SCC (ng/ml)
>1.5 31 3.14 (1.52–6.49) <0.01 2.53 (1.28–4.98) <0.01 8 2.62 (0.76–9.04) 0.13 2.60 (0.77–8.75) 0.12
≤1.5 99 1 1 30 1 1
Tumor diameter (cm)
>3 47 1.23 (0.64–2.40) 0.53 1.03 (0.56–1.89) 0.93 16 1.02 (0.33–2.95) 0.98 1.03 (0.35–3.19) 0.91
≤3 83 1 1 22 1 1
Pathological stage
IB 56 1.25 (0.56–2.11) 0.80 1.18 (0.65–2.14) 0.58 17 1.27 (0.42–3.79) 0.67 1.32 (0.44–3.95) 0.62
IA 74 1 1 21 1 1
Lymphatic permeation
Present 24 1.05 (0.46–2.40) 0.90 1.14 (0.57–2.32) 0.71 7 1.68 (0.37–7.63) 0.51 1.62 (0.36–7.41) 0.53
Absent 106 1 1 31 1 1
Vascular invasion
Present 17 1.26 (0.49–3.26) 0.63 2.22 (1.02–4.82) 0.04 7 10.7 (3.09–37.3) <0.01 8.12 (2.53–26.0) <0.01
Absent 113 1 1 31 1 1
Pleural invasion
Present 23 1.80 (0.74–3.57) 0.22 2.06 (1.06–3.99) 0.03 4 1.07 (0.40–2.87) 0.90 1.05 (0.39–2.82) 0.93
Absent 107 1 1 34 1 1
p-SqCCs, peripheral squamous cell carcinomas; c-SqCCs, central squamous cell carcinomas; OS, overall survival; RFS, recurrence-free survival; HR, hazard ratio; CI, confidence 
interval; BI, Brinkman index; CEA, carcinoembryonic antigen; SCC, squamous cell carcinoma antigen
TABLE 2.  (Continued)
Variables
p-SqCCs c-SqCCs
n
OS RFS
n
OS RFS
HR (95%CI) p -value HR (95%CI) p -value HR (95%CI) p -value HR (95%CI) p value
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results, SqCCs should be classified under respectively differ-
ent categories with reference to its location.
Tumor markers also have been investigated as prognos-
tic factors because they are simple parameters to measure and 
can consistently be evaluated as normal or abnormal in dif-
ferent institutions if a cutoff value is set. Among these tumor 
markers, not only SCC, but also cytokeratin 19 fragment 
(CYFRA) are generally identified as helpful markers among 
patients with SqCC. In our institutes, SCC is measured within 
1 month before surgery, whereas CYFRA is not routinely 
evaluated. The difference of reliability among them remains 
unclear. Kagohashi et al.16 demonstrated that there is no sta-
tistical difference in sensitivity between SCC and CYFRA 
among SqCC patients. SCC has been used as a reliable and 
popular marker for SqCC in Japan and in European countries. 
Takeuchi et al.17 concluded that the T and N factors are not 
associated with the positive rate of serum SCC among SqCC 
patients. They also asserted the incidence of an elevated serum 
SCC concentration preoperatively is not correlated with sur-
vival in SqCC patients. However, the number of enrolled 
patients was small in the study (n = 49). In our analysis, T 
and N status were both significantly correlated with the serum 
SCC level (data not shown). We also revealed the serum SCC 
level accurately reflects survival status. P-SqCCs patients 
with high serum SCC may already have some micro-metas-
tasis at the time of operation. Taking these facts and results 
in account, we emphasize that not only pathological features, 
but also serum SCC level should be regarded as criteria into 
upstaging.
In a 2012 study of patients with small p-SqCCs, 
Nagashima et al.18 proposed that older age, high serum CEA 
level, and nodal metastasis are significant prognostic fac-
tors. As they reported, univariate analysis for all stage SqCCs 
shows that high serum CEA level was associated with poor 
OS outcome (p = 0.01). However, CEA was not associated 
with poorer survival for patients with stage I p-SqCCs in our 
study (p = 0.10). Tas et al.19 demonstrated that the serum CEA 
level was associated with advanced stage of lung SqCCs, but 
not with early stages. The evaluation of preoperative serum 
CEA level might be useful in not early but advanced stage of 
p-SqCC patients.
Hamada et al.20 demonstrated that postoperative adju-
vant chemotherapy with uracil-tegafur lead to the improve-
ment of OS for stage I lung adenocarcinoma patients, however 
equivocally for SqCC patients. 21 No clinical trials support that 
adjuvant chemotherapy is effective for pathological stage I 
p-SqCC patients up to now. However, as shown in Figure 3 and 
Table 3, stage I p-SqCC patients with high serum SCC level 
or vascular invasion had a significantly high recurrence rate. 
As noted above, we proposed T1 p-SqCCs with high serum 
SCC level or vascular invasion should be upgraded to T2a 
and pleural invasion. This stage upgrade reflected clearly RFS 
condition among patients with p-SqCCs. The incidence of 
p-SqCCs has increased recently, further clinical trial based on 
the clinicopathological findings should be performed whether 
or not the postoperative chemotherapy should be indicated in 
stage I patients.
Significantly strong relationship between the smoking 
status and the development of SqCCs has been reported from 
a lot of epidemiologic and laboratory studies.22 Smoking habit 
is an important risk factor not only for lung cancer, but also 
for cardiovascular disease and chronic obstructive pulmonary 
disease. Some SqCCs cases are complicated with an obstruc-
tive ventilatory disturbance due to smoking habit preopera-
tively. Although major lung resection has been the standard 
operation of choice for NSCLC,23 we sometimes cannot help 
performing lesser operation such as segmentectomy and par-
tial resection because of patient’s poor pulmonary function. 
Sakurai et al.12 showed skipping metastasis of N2 disease was 
quite rare in p-SqCCs. They suggested that limited resection 
could be curable for peripheral SqCCs on the evidence of no 
hilar lymph node metastasis by frozen section pathological 
TABLE 3.  Independent Prognostic Factors for Peripheral Squamous Cell Carcinoma Patients of All Stages and Pathological 
Stage I on Multivariate Analysis
Variables Reference HR (95%CI) p -value
All stages
OS Pulmonary disease Present 2.98 (1.77–5.03) <0.01
Serum SCC Abnormal 2.16 (1.28–3.68) <0.01
Nodal metastasis Present 1.97 (1.13–3.46) 0.02
Vascular invasion Present 2.19 (1.24–3.86) <0.01
Pleural invasion Present 1.83 (1.08–3.11) 0.03
RFS Serum SCC Abnormal 1.89 (1.21–2.97) <0.01
Vascular invasion Present 2.18 (1.33–3.56) <0.01
Pleural invasion Present 1.77 (1.12–2.81) 0.01
Pathological stage I
OS Serum SCC Abnormal 2.53 (1.28–4.98) <0.01
RFS Serum SCC Abnormal 1.95 (1.25–3.07) <0.01
Vascular invasion Present 2.11 (1.29–3.45) <0.01
Pleural invasion Present 1.78 (1.12–2.82) 0.01
OS, overall survival; RFS, recurrence-free survival; HR, hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma antigen.
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diagnosis. Statistical differences in OS and RFS between stan-
dard and limited operation are not obviously detected in our 
survey. To validate whether or not limited operation can lead 
the equal survival outcome as one with standard operation, 
larger clinical surveys are needed to perform prospectively in 
multiinstitution.
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FIGURE 2.  Recurrence-free survival curves for patients with p-SqCCs of all stages according to vascular invasion (A), pleural 
invasion (B), and serum SCC level (C). Recurrence-free survival curves for patients with p-SqCCs of pathological stage I accord-
ing to vascular invasion (D), pleural invasion (E), and serum SCC level (F). p-SqCCs, peripheral squamous cell carcinomas; SCC, 
squamous cell carcinoma antigen.
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This study has some potential limitations. First, because 
the patient number was moderate and the study may have not 
had enough power to detect significant differences in survival 
for factors with small impacts on prognosis. Second, not all 
the patients who were diagnosed to have over stage II p-SqCC 
received adjuvant chemotherapy due to their health condition 
and interest. However, in conclusion, high preoperative serum 
SCC level, pleural and vascular invasions were independent 
poor prognostic factors for p-SqCCs. We emphasize that not 
only pleural invasion, but also high serum SCC level and vas-
cular invasion should be regarded as criteria into upstaging in 
the forthcoming TNM classification. Taking these prognostic 
factors in account, we should make more careful follow-up 
plans and choose useful therapeutic options such as adju-
vant chemotherapy, which might lead to the improvement of 
patient’s prognosis. Furthermore to elucidate the malignant 
behavior of p-SqCCs, further clinicopathological studies are 
needed to perform prospectively in multiinstitution, leading to 
more useful therapeutic options.
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